Microplate-based automatic blood grouping analyzer Metis of Aikang MedTech Co., Ltd. (henceforth referred to as Aikang) received approval for marketing in 2015; and its MGT-based automatic blood grouping analyzer Aigel received approval for marketing in 2016.

Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

Chinese single-cell technology firm Singleron Biotechnologies said on Monday that it has acquired Singapore-based Proteona.

The updated prospectus shows that Adicon additionally disclosed financial data for 2021 and other content. According to the prospectus, Adicon's operating income in 2021 will be CNY 3.380 billion.

On March 2, the FTSE Russell Day announced the results of the quarterly audit changes of the FTSE China A50 and other indices.

One of the most promising avenues in treating cancer is to restore our immune system’s ability to recognize and attack cancerous cells.

AnchorDx, a world-leading developer of cancer screening and early detection solutions, is delighted to announce that Dr. Marina Bibikova has come on board as Chief Scientific Officer (CSO).

Moderna and Thermo Fisher Scientific Inc.announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing in the U.S. of Spikevax®, Moderna’s COVID-19 vaccine, and other investigational mRNA medicines in its pipeline.

Belgian diagnostics firm MDxHealth on Wednesday reported a 20 percent year-over-year increase in revenues for 2021 on higher demand for its ConfirmMDx prostate cancer test.

Lucid Diagnostics on Thursday announced that its LucidDx Labs subsidiary has acquired certain licenses and other related assets from ResearchDx enabling it to operate a new CLIA-certified, CAP-accredited clinical laboratory in Lake Forest, California.

Today, Beckman Coulter announced that Dr. Tiffany Jiang, Senior Vice President & General Manager, retired early effective February 28.

New research led by Queen Mary University of London and Barts Health NHS Trust suggests that biochemical analysis of brain tissue could be used for diagnosis and prognosis of severe traumatic brain injury (TBI) to improve patient outcomes and save billions in future clinical trials.